Cambridge, MA, Rotterdam, Netherlands and Suzhou, China, November 14, 2022 /PRNewswire/ — Harbor BioMed (HK: 02142) today announced the establishment of a wholly-owned subsidiary, Nona Bio, to provide next-generation antibody and biotherapeutic solutions to partners from discovery to IND. New subsidiary will leverage Harbor BioMed’s technology platform, including its Harbor Mice® and HBICE® for the generation of fully human antibodies and has demonstrated expertise in discovery and development, as well as an innovative business model, making these technologies widely available to biotech and biopharmaceutical companies and academic institutions.
Nona Biosciences wisely opens up access to Harbor Mice, its industry-leading patented technology platform® With a flexible business model, remove platform barriers for partners, so that platforms and technologies can truly empower the discovery and development of next-generation innovative therapies around the world.This new approach offers a significant new alternative to the company’s Harbor Mice® Platform Licensing.
“The biopharmaceutical industry is moving towards more complex whole-human biotherapeutics, such as bispecific antibodies and antibody-drug conjugates, and cell therapies including CAR-T, CAR-NK, and mRNA-based drugs.” Wang Jinsong, Founder, Chairman and Chief Executive Officer of Harbor BioMed. “Nona Biosciences will leverage our strong track record in biological discovery and development, as well as our validation of Harbor Mice® platform, has been widely adopted by pharmaceutical and biotech companies as well as academic centers. We believe that our platform, model, and experienced team will enable our partners to drive innovation in biotherapeutics that will benefit the industry and, ultimately, patients around the world. “
Since Harbor BioMed was founded six years ago, the company has built and applied its discovery platform to create a broad therapeutic pipeline.harbor mouse® The platform has been validated by more than 50 corporate and academic partners, including Pfizer, Eli Lilly, and Dana-Farber Cancer Institute. More than 10 projects have entered the clinical trial stage.
Oneona Biosciences proprietary integrated technology platform
Nona Biosciences’ new research and discovery services will include an integrated suite of technologies to provide a comprehensive solution for antibody discovery, engineering and development.
Discovery platform anchored by Harbor Mice® Techniques for generating fully human antibodies to a variety of novel biomolecules. These technologies enable fully human monoclonal antibodies in the classical two light and two heavy chain (H2L2) format and the heavy chain only (HCAb) format. These technologies provide new approaches for the development of immuno-oncology therapies, immune cell therapies, multispecific antibody engineering, and antibody-drug conjugate development.
The platform also includes HBICE®, Harbor BioMed’s HCAb-based immune cell engager bispecific platform. The HBICE® The platform offers unique advantages for the development of novel bispecific antibodies.
Nona Biosciences combines these innovative platforms with premium services covering antigen preparation, animal immunization, single B cell screening, antibody lead generation and engineering, developability assessment and pharmacology evaluation.
About Nona Biosciences
Nona Bio (a wholly-owned subsidiary of HBM Holdings, HKEX: 02142) is a global biotechnology company dedicated to providing innovative solutions from “Idea to IND” (“I to ITM value”), from target validation and antibody discovery to preclinical studies.Utilizing the advantages of Harbor Mice, comprehensive antibody and antibody-related discovery services in various forms, from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, etc.® platform and experienced therapeutic antibody discovery team.
Hong Kong rat® Generate fully human monoclonal antibodies in the classical two light chain and two heavy chain (H2L2) format as well as the heavy chain only (HCAb) format.Integrate the mouse® Nona Biosciences and its single B cell cloning platform are focused on advancing the global discovery of transformative next-generation medicines. For more information, please visit www.nonabio.com
Sources Hebo Medicine